Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $212.85M.
ENTERPRISE VALUE (EV)
$212.85M
Nautilus Biotechnolgy, Inc.
Market Cap
$225.24M
Enterprise Value (EV)
$212.85M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $225.24M | $212.85M |
| Biodesix, Inc. (BDSX)vs › | $227.60M | $269.40M |
| Vogenx Inc. (VOGX)vs › | $227.91M | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | $189.92M |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | $152.55M |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | $222.89M |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | N/A |
| InflaRx N.V. (IFRX)vs › | $232.72M | $66.34M |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | $208.23M |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | $235.27M |
Market Cap
$225.24M
Total Debt
$0.00
Cash
$12.39M
Enterprise Value
$212.85M
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
